CSL to acquire majority stake in
Chinese plasma fractionator ASX Announcement

13-June-2017 — The transaction will better serve patients with rare and serious diseases in this important high growth market... More.

Applications Open for CSL Centenary Fellowship Program
Applications Open for CSL Centenary Fellowship Program

01-June-2017 — $1.25 Million Funding Available to Australia’s Best and Brightest Biomedical Researchers. More.


Other recent news:

23-June-2017 — CSL announced that the FDA has approved CSL Behring’s HAEGARDA®. More.
12-April-2017 — CSL remains highly confident that CSL830 does not infringe any valid claim of the Shire ViroPharma patent and will vigorously defend against the claims. More.
15-February-2017  — CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of $806 million for the six months ended 31 December 2016, up $87 million or 12% on a reported basis when compared to the prior comparable period (PCP). More.

© 2017 CSL Limited